Pharmaceutical

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based…

2 weeks ago

Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,…

2 weeks ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.…

2 weeks ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their…

2 weeks ago

CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE…

2 weeks ago

Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault…

2 weeks ago

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage…

2 weeks ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov.…

2 weeks ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United…

2 weeks ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…

2 weeks ago